Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07565220 · ClinicalTrials.gov registry record · Phase 1
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
A Phase 1 study, sponsored by Sawa Ito, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT07565220 is a Phase 1 study that is actively recruiting participants, run by Sawa Ito, MD. The registered enrollment target is 48 participants.
The verdict
NCT07565220, a Phase 1 study, is actively recruiting participants, sponsored by Sawa Ito, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This phase 1 trial will investigate the safety and effectiveness of Thiotepa, Busulfan, and Fludarabine (TBF) conditioning regimen with post-transplant cyclophosphamide (PTCy) in HLA-matched related or unrelated donor allogeneic stem cell transplantation (alloSCT).
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Thiotepa
- PROCEDURE PBSC infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2030-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07565220
The ClinicalTrials.gov registry entry for NCT07565220 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sawa Ito, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fludarabine is the first listed.
NCT07565220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07565220 about?
NCT07565220 is a clinical study titled "Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies". This phase 1 trial will investigate the safety and effectiveness of Thiotepa, Busulfan, and Fludarabine (TBF) conditioning regimen with post-transplant cyclophosphamide (PTCy) in HLA-matched related or unrelated donor allogeneic stem cell transplantation (alloSCT).
What is the current status of trial NCT07565220?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2026-08-01. Estimated completion is 2030-11-01.
What interventions are being tested in trial NCT07565220?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Thiotepa (DRUG), PBSC infusion (PROCEDURE).
Who is sponsoring clinical trial NCT07565220?
This trial is sponsored by Sawa Ito, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.